ArticleEuropean thyroid journal2022
2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
Article in European thyroid journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06134830 (Clinical Outcome and Quality of Life in Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.), which is not on this map. Cited by 100 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Outcome and Quality of Life in Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.
Who cites it
100 citing papers in PubMed, 3 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Pooled it
- The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery.Endocrine journal · 2025Guideline
- Medium- and long-term recurrence after radioiodine therapy for differentiated thyroid carcinoma with recombinant human thyrotropin: a meta-analysis.Frontiers in endocrinology · 2024Pooled it
- From bench to bedside: the evolving role of iodine in thyroid cancer management.Nature reviews. Endocrinology · 2026Review
- Predicting radioiodine therapy response in advanced and recurrent thyroid cancer.Endocrine-related cancer · 2026Article
- Optimal timing of post-therapeutic [BMC medical imaging · 2026Review
- [New developments in endocrinology/diabetology].Innere Medizin (Heidelberg, Germany) · 2026Review
- Indications and Complications of Total Thyroidectomy in the Management of Thyroid Diseases: A Five-Year Retrospective Study in a Greek Population.Acta medica academica · 2026Article
- Association of radioactive iodine treatment with survivorship symptoms and primary care utilisation in women of reproductive age with thyroid cancer: a retrospective cohort study.Family medicine and community health · 2026Article
- Long-term relative survival with and without radioiodine in patients with low-risk thyroid cancer: a SEER based analysis of histologic subtypes and risk factors.European journal of nuclear medicine and molecular imaging · 2026Article
- Development of a clinical prediction model to guide the selective use of SPECT/CT in papillary thyroid cancer.Quantitative imaging in medicine and surgery · 2026Article
- A computational framework for optimizing radioiodine therapy protocols in metastatic thyroid cancer.Scientific reports · 2026Article
- De-escalation implementation in low-risk papillary thyroid cancer: a nationwide survey.Endocrine connections · 2026Article
- No reinduction of clinically relevant radioiodine uptake after lenvatinib treatment in radioidine-refractory differentiated thyroid cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Promise and pitfalls of AI chatbots in complex decision-making for thyroid nodules and papillary thyroid cancer.European thyroid journal · 2026Article
- The 2025 ATA guidelines for differentiated thyroid Cancer - Ten years of professional debate and measured progress.European journal of nuclear medicine and molecular imaging · 2026Article
- Optimal extent of thyroidectomy in clinically node-negative unilateral papillary thyroid carcinoma >1 cm and ≤4 cm.Gland surgery · 2026Article
- The Role ofMedical sciences (Basel, Switzerland) · 2026Review
- State of the Art on Thyroid Cancer Biology and Oncology.Biomedicines · 2026Review
- Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes.Frontiers in medicine · 2026Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patients' risk stratification. Although beneficial effects of radioiodine are undisputed in high-risk patients, controversy remains in intermediate-risk and some low-risk patients. Since the last consensus on post-surgical use of RAI in DTC patients, new retrospective data and results of prospective randomized trials have been published, which have allowed the development of a new European Thyroid Association (ETA) statement for the indications of post-surgical RAI therapy in DTC. Questions about which patients are candidates for RAI therapy, which activities of RAI can be used, and which modalities of pre-treatment patient preparation should be used are addressed in the present guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.